Comparative analysis of adverse events between sacubitril/valsartan and valsartan using the FAERS database: a disproportionality analysis
database[Title] 2025-11-23
Summary:
CONCLUSIONS: Sacubitril/valsartan and valsartan exhibit distinct AE risk profiles in cardiovascular disease treatment, underscoring the need for large-scale clinical trials and mechanistic studies on sacubitril to validate these findings.